Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5% Consolidated net revenue of € 1,743.1 million in the...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi...
L’étude LINC 4 a démontré la supériorité d’Isturisa® (osilodrostat) comparé au placebo pour normaliser le cortisol au cours de la phase de 12 semaines en double aveugle, randomisée de l’étude (77...
RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER...
Statistically significant results from the pivotal Phase III LINC 4 study demonstrate that Isturisa® (osilodrostat) provides rapid and sustained normalisation of mean urinary free cortisol levels...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.85 | 3.50710900474 | 52.75 | 55.1 | 52.45 | 341189 | 54.36696312 | DE |
| 4 | 4.3 | 8.54870775348 | 50.3 | 55.1 | 49.6 | 258623 | 53.24933102 | DE |
| 12 | 0.35 | 0.645161290323 | 54.25 | 55.1 | 48.58 | 276774 | 51.82761251 | DE |
| 26 | 3.55 | 6.95396669931 | 51.05 | 55.1 | 47.98 | 255431 | 51.60246698 | DE |
| 52 | 4.52 | 9.02555910543 | 50.08 | 55.1 | 47.28 | 238639 | 50.98601865 | DE |
| 156 | 3.14 | 6.10182666148 | 51.46 | 55.1 | 34.52 | 236392 | 45.62491321 | DE |
| 260 | 15.24 | 38.7195121951 | 39.36 | 57.9 | 28.26 | 279717 | 45.19050007 | DE |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
